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Abstract
Neurotrophin receptors of the Trk family play a vital role in the survival of developing neurons and the process of axonogenesis. The Trk
family are receptor protein tyrosine kinases (RTKs) and their signalling in response to neurotrophins is critically dependent upon their ability to
transphosphorylate and act as signalling centres for multiple adaptor proteins and distinct, downstream pathways. Such phosphotyrosine signalling
also depends upon the appropriate counter-regulation by phosphatases. A large family of receptor-like protein tyrosine phosphatases (RPTPs) are
also expressed in developing neurons and in this study we have examined the ability of the phosphatase PTPσ to interact with and regulate Trk
proteins in transfected HEK 293T cells. PTPσ can bind differentially to Trk proteins, binding stably in complexes with TrkA and TrkC, but not
TrkB. The transmembrane domains of PTPσ and TrkA appear to be sufficient for the direct or indirect interaction between these two receptors.
Furthermore, PTPσ is shown to dephosphorylate all three Trk receptors and suppress their phosphorylation in the presence of neurotrophins. In
addition, overexpression of PTPσ in primary sensory neurons in culture inhibits neurite outgrowth without affecting the short-term survival of
these neurons. PTPσ can thus show differential complex formation with different Trk family members and in neurons can selectively target the
neurite-forming signalling pathway driven by TrkA.
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During development, a multitude of extrinsic factors work
together to stimulate axonal growth and guide axons to their
final targets. This establishes the synaptic network upon which
the mature function of the nervous system depends. Avariety of
receptors have been shown to interpret axon growth and
guidance cues, including those in the Trk, Eph, DCC, Robo and
Neuropilin families [1,2]. One common mechanism used by
many of these receptors to regulate downstream signalling
pathways and therefore the response of the cell, is via reversible
tyrosine phosphorylation. The balance of tyrosine phosphoryla-
tion in the cell is controlled by two major groups of proteins, the
tyrosine kinases, which include Trk and Eph members, and the⁎ Corresponding author. Tel.: +44 207 9052244; fax: +44 207 8314366.
E-mail address: astoker@ich.ucl.ac.uk (A. Stoker).
0167-4889/$ - see front matter © 2007 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamcr.2007.06.008tyrosine phosphatases. Although much is known about the roles
of receptor protein tyrosine kinases (RTKs) in cell signalling,
much less is known about the signalling mechanisms of their
counterbalancing enzymes, the receptor protein tyrosine
phosphatases (RPTPs).
Twenty-one human RPTPs have been identified [3], with
homologues and orthologues in both vertebrates and inverte-
brates. All RPTPs share a highly conserved intracellular
domain, consisting of either one or two phosphatase motifs
[4]. For many, however, only the membrane-proximal phos-
phatase domain (D1) is catalytically active, with the second
phosphatase domain (D2) exhibiting little or no activity [5,6].
The RPTPs have been further classified into eight subfamilies
according to their extracellular domain structure [4] and many
are expressed at high levels in the developing nervous system
[7,8]. Among the best characterised of the RPTPs are those of
the type IIa subfamily. These proteins are akin to cell adhesion
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fibronectin type III repeats in their extracellular domain [8,9].
Type IIa enzymes include vertebrate LAR, PTPδ and PTPσ,
leech HmLAR1/2 and Drosophila DLAR and DPTP69D, each
of which has been shown to play important roles in axon growth
and guidance [10].
Evidence for the role of type IIa RPTPs in axon guidance
came initially from studies inDrosophila. DLAR and DPTP69D
are required for correct axonal targeting of motor neurons
[11,12], midline commissural neurons [13] and photoreceptors
[14,15]. In vertebrates, type IIa RPTPs were found to play
related roles. Overexpression of a dominant negative form of
PTPδ inhibited retinal ganglion cell (RGC) neurite outgrowth,
while a dominant negative form of PTPσ enhanced RGC neurite
elongation [16]. Mice deficient in type IIa RPTPs also exhibit
defects which are indicative of initial neurite outgrowth and
guidance problems [17–23]. In addition, removal of either LAR
or PTPσ affects the regenerative capacity of neurons. However,
while LAR deficient animals show a delay in nerve regeneration
and collateral nerve sprouting after injury [24,25], PTPσ defi-
cient animals exhibit enhanced nerve regeneration [26–28].
Thus it appears that each of the type IIa RPTPs may have both
divergent and complementary roles in axon growth and guidance
[23].
Relatively little is known about the signalling mechanisms of
type IIa RPTPs, or how they modulate axon guidance. In
Drosophila and in vertebrates, type IIa RPTPs have been found
to interact with various proteins that regulate the actin
cytoskeleton, including the Abl tyrosine kinase [29], and the
guanine nucleotide exchange factor, TRIO [30]. Type IIa
RPTPs also affect cell adhesion by association with cadherins
and β-catenin [31–33]. The activity of various receptor tyrosine
kinases also appears to be directly regulated by type IIa RPTPs
[34–38]. Among these are the Trk receptors, which have long
been known to influence axon growth [2]. Trk proteins are
receptors for the neurotrophin family of growth factors, namely
Nerve Growth Factor (NGF), Brain Derived Neurotrophic
Factor (BDNF), Neurotrophin 3 (NT-3) and Neurotrophin 4/5
(NT4/5). Generally, NGF interacts preferentially with TrkA,
BDNF and NT4/5 with TrkB, and NT3 with TrkC. Like most
RTKs, ligand binding causes receptor dimerisation, autopho-
sphorylation on tyrosine residues and kinase activation. It has
been shown that the Type IIa RPTP LAR regulates signalling of
TrkA and TrkB [36–39]. For example, downregulation of LAR
signalling in PC12 cells augments neurite outgrowth, decreases
cell death and activates TrkA signalling [36,38]. LAR also
activates TrkB signalling via the pp60src tyrosine kinase [39].
Furthermore, LAR has recently been found in a complex with
TrkA [38] and TrkB [39].
Our studies on PTPσ have shown that this phosphatase also
affects neurite outgrowth [16,40,41], while others have shown
that it influences nerve repair [26–28]. In this study we have
examined whether PTPσ interacts with proteins of the Trk
family. We find that while PTPσ can be found in stable
complexes with TrkA and TrkC but not TrkB when co-
expressed in HEK 293T cells, the phosphatase can still cause
dephosphorylation of all three Trks. In addition, we demonstratethat the overexpression of PTPσ in chick dorsal root ganglion
neurons limits NGF-induced neurite outgrowth, but not neuron
survival. These studies therefore indicate that PTPσ exhibits
distinct physical interactions with different Trk receptors, and
may be able to regulate specific aspects of the TrkA signalling
pathway in neurons.
2. Materials and methods
2.1. DNA plasmid constructs
The generation of the chick PTPσ expression vectors with an amino-
terminal FLAG epitope tag and C-terminal tag consisting of either 3xMYC-tags
or 1xHA-tag, plus the generation of vectors encoding proteins PTPσICD and
PTPσECD, is described elsewhere [42]. In summary, the proteins were encoded
by cDNA fragments inserted into vector p3XFLAG-MYC-CMVTM-25
(Sigma), with PTPσ ECD encoding bp85–bp2650 of PTPσ, and PTPσ ICD
encoding bp2533 to the stop codon of PTPσ1. The rat TrkA cDNA was
subcloned into the pCDNA3 expression vector. The rat TrkA Trunc constructs,
pCMV-TrkA Trunc80, pCMV-TrkA Trunc30 and pCMV-TrkA Trunc10 were
previously described [43] as pCMV-TrkA Trunc12, pCMV-TrkA Trunc2 and
pCMV-TrkA Trunc respectively. Two additional TrkA truncation mutants were
generated: pCDNA3-TrkATrunc6 and pCDNA3-TrkATrunc2. Briefly, using a
PCR strategy, the full-length rat pCDNA3-TrkA construct was used as a
template, and primers incorporating flanking restriction sites and a 3′ in-frame
stop codon were used to generate two intracellular deletions mutants of TrkA
that contain either 6 or 2 intracellular residues only (Trunc6 and Trunc2
respectively). The PCR products were cloned into pCDNA3 at the EcoRI site
and verified by automated DNA sequencing. The rat TrkA ICD construct, which
deletes most of the TrkA ectodomain, was previously described as TrkAdel-
taECD and was provided by JC Arevelo [44]. The pCMX TrkB-MYC(rat) and
pCMX TrkC-MYC(rat) constructs were provided by PA Barker [45]. pMAX
GFP was provided by Amaxa biosystems with the chicken neuron nucleofector
kit (Amaxa, UK). The HA-tagged, mouse PTPα cDNA expression vector was
supplied by Dr. J. den Hertog.
2.2. Antibodies
Anti-FLAG M2 monoclonal antibody was obtained from Sigma-Aldrich
(Sigma-Aldrich, UK). Anti-HA and anti-HA-peroxidase, clone 3F10 were
provided by Roche (Roche Applied Science). Anti-MYC tag (clone 4A6), anti-
phosphotyrosine (clone 4G10) and anti-TrkA (raised against the extracellular
domain) were supplied by Upstate (UK). Anti-TrkA (763):sc118 (raised against
the C-terminus) was obtained from Santa Cruz (Santa Cruz biotechnology,
USA). This anti-TrkA antibody recognises both phosphorylated and non-
phosphorylated forms of TrkA. Rabbit anti-chick TrkAwas kindly provided by
Dr. L Reichardt [46]. Anti-neuronal Class III β-tubulin (TUJ1) was supplied by
(Covance Research Products Inc. USA).
2.3. Transfection, co-immunoprecipitation and western blotting
DNAvectors were transfected into HEK293Tcells (ATCC, Manassas, USA)
using standard calcium phosphate methods. Cells were lysed 48 h after
transfection in 1% Triton X-100, 50 mM Tris–HCl pH 7.5, 150 mM NaCl, with
protease inhibitors (Complete, Roche). Where necessary, phosphatase activity
was inhibited in the lysates by the addition of 2 mM sodium orthovanadate to the
lysis buffer. Lysates were centrifuged at 13000 rpm for 30 min at 4 °C to remove
cells debris and protein concentrations were estimated using the Bradford
method. For immunoprecipitation, approximately 1 mg of total protein lysate
was incubated with the specific antibody overnight at 4 °C and antibodies were
then purified using protein G or protein A sepharose beads (Upstate, UK),
according to manufacturer's recommendations. Sepharose beads were washed 4
times in 50 mM Tris pH 7.5, 150 mM NaCl, 0.2% Triton X-100, followed by 1
wash in 50 mM Tris pH 7.5, 150 mM NaCl (TBS). Laemmli buffer with 10% β-
mercaptoethanol was added to the beads and immunoprecipitated samples were
analysed by polyacrylamide gel electrophoresis (PAGE). Gels were transferred
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buffer (25 mM Tris, 192 mM Glycine, 20% Methanol). Membranes were
blocked overnight with 10% dried milk powder in TBST (TBS, 0.2% Tween-
20), or in 5% BSA, TBST (when using anti-phosphotyrosine antibody) before
addition of diluted antibody for 1 h. Filters were washed 3 times in TBST before
addition of HRP-conjugated secondary antibodies for 1 h. HRP antibody was
detected with ECL Plus as recommended by the manufacturer (Amersham
Biosciences, UK). Films were scanned on a BioRad GS-800 densitometer and
relative band intensities were measured using Quantity One software. For TrkA
immunoprecipitation and immunodetection, the amino-terminal antibody was
used, except where the TrkAICD was being used. In cultures where NGF
treatment was used, NGF (Promega, Southampton, UK) was added at a
concentration of 100 ng/ml; treatments were for 20 min prior to cell lysis. BDNF
(Insight Biotechnology Ltd) was used at 50 ng/ml for 30 min, and rhNT-3 (R&D
Systems) was used at 20 ng/ml for 30 min.
2.4. Chick dorsal root ganglion dissection and nucleofection
Dorsal root ganglia were dissected from day 7 chick embryos. Cells were
dissociated in DMEM with 10 μg/ml DNase1, 0.25 mg/ml Trypsin (Sigma-
Aldrich, UK) for 30 min at 37 °C, followed by full dissociation using 19G
needles. Cells were transfected by nucleofection using the chicken neuron
nucleofector kit (Amaxa Biosystems, UK) according to the manufacturer's
instruction Two million cells were transfected with 2 μg pMAX-GFP (Amaxo
biosystems) and 2 μg plasmid DNA. Cells were pre-plated in DMEM, 10% fetal
calf serum (FCS), 2% chick serum for 1 h to partially purify the neuronal
population, before plating on poly-L-lysine (Sigma-Aldrich, UK) and fibronectin
(Sigma) coated plates with 100 ng/ml nerve growth factor (NGF) (Promega).
Cells were fixed in 4% paraformaldehyde 24 h after plating and GFP positive
cells were counted.
2.5. Immunohistochemistry and cell counts
To examine the number of transfected neurons with neurites, GFP-positive
cells with neurites longer than 1 cell body length were counted in each
experimental condition within a standard area of each tissue culture plate, and
expressed relative to the number of GFP positive neurons with neurites in the
control (pCVM25+NGF). In each independent experiment, greater than
50 neurons were counted per plate for each treatment class. For total neuron
numbers, cells were immunostained with neuronal Class III β-tubulin antibody
TuJ1 (CRP Inc, USA), using an anti-mouse Alexa568 conjugated secondary
antibody (Molecular Probes, UK) for detection. GFP positive/β-tubulin positive
cells were counted in at least 3 independent cultures, with greater than 200 cells
counted per experiment.3. Results
3.1. PTPσ exhibits differential interactions with TrkA, TrkB
and TrkC
PTPσ, TrkA, TrkB and TrkC are expressed in overlapping
patterns within the developing nervous system, including
sensory neurons [7,47,48] and each has been implicated in the
regulation of neurite outgrowth (reviewed in [2,10]). A close
relative of PTPσ, LAR, also interacts with and regulates Trk
enzymes [39]. It is possible therefore that PTPσ also operates in
the same phosphotyrosine signalling pathway as the Trk
receptors. To determine first if PTPσ interacts with any of the
Trk receptors, PTPσ was expressed with each Trk receptor in
HEK 293T cells and interactions were examined by co-
immunoprecipitation (Fig. 1). HEK 293T cells are a highly
transfectable human embryo kidney line, expressing SV40 large
Tantigen [49]. In HEK 293Tcells, three different forms of TrkAare produced, namely an immature 80 kDa protein, a 110-kDa
glycosylated protein (gp110) and the fully mature 140 kDa
protein (gp140) [50] (Fig.1A, top panel). In these cells PTPσ
undergoes two proteolytic processing events to generate
membrane spanning intracellular domain fragments of approxi-
mately 75 kDa and 85 kDa (as detected by the C-terminal HA
tag, Fig. 1G protein forms 4 and 5) and complementary,
extracellular domain fragments of approximately 85 kDa and
80 kDa (detected by the amino-terminal FLAG tag; Fig. 1G
protein forms 2 and 3, also documented in ref. 42). In addition, a
full-length, uncleaved form of the PTPσ (approximately
165 kDa) is produced (Fig. 1G; form 1). Both cleaved and
uncleaved forms of PTPσ were found to co-precipitate
efficiently with TrkA (Fig. 1A, B). Similarly, immunoprecipita-
tion of PTPσ, followed by detection with the polyclonal TrkA
antibody, showed that TrkA can be co-precipitated (Fig. 1B). It
was noted that in some experiments, co-expression of PTPσ
with TrkA resulted in increased amounts of the mature TrkA
form (Fig. 1A, E). This was not found consistently (see Fig. 1B)
and so its meaning is currently unclear, although related
findings have been documented for other RTK/PTP combina-
tions [51].
The myc-tagged TrkC receptor produces a mature 145 kDa
protein and an immature protein approximately 120 kDa [45].
Each of these proteins was found to co-immunoprecipitate with
both the cleaved and uncleaved PTPσ (Fig. 1E, F). In contrast,
following immunoprecipitation of myc-tagged TrkB, only trace
amounts of interacting PTPσ at most were ever observed, even
with heavy overexpression of PTPσ (Fig. 1C). Co-precipitated
TrkB proteins were not detected at all following immunopre-
cipitation of PTPσ (Fig. 1D; middle panel is exposed 300×
longer than the top and bottom panels). A comparison between
co-immunoprecipitation experiments therefore indicates that
TrkA and TrkC interact with PTPσ in a complex stable enough
to be precipitated, whereas TrkB interacts distinctly and only
very weakly. These data do not indicate currently whether it is a
direct or indirect interaction between PTPσ and TrkA and TrkC.
Several other RPTP genes are also expressed in sensory
neurons [52]. One of these, type IV RPTP PTPα, was tested to
see if it could bind to TrkA under co-immunoprecipitation
conditions. PTPα was found not to co-precipitate with TrkA,
even when PTPα was very heavily overexpressed (Fig. 2, lane
5). This indicates that the interaction of PTPσ with TrkA is
selective.
3.2. PTPσ causes dephosphorylation of Trk proteins
Following neurotrophin binding, the Trk receptors undergo
dimerisation and autophosphorylation on tyrosine residues in
their intracellular domains [53]. Receptor autophosphorylation
activates the kinase domain allowing the subsequent binding
and phosphorylation of downstream proteins [54]. To determine
whether PTPσ can affect the phosphorylation of the TrkA
receptor, we first examined the level of tyrosine phosphoryla-
tion in HEK 293T cells overexpressing TrkA, either with or
without PTPσ (Fig. 3). Cells were stimulated with Nerve
Growth Factor (NGF) 20 min prior to lysis to activate TrkA.
Fig. 1. Reciprocal co-immunoprecipitation of PTPσ with TrkA, TrkB and TrkC. PTPσ proteins containing an N-terminal FLAG-tag or a C-terminal HA-tag were co-
expressed in HEK 293T cells with either TrkA (A, B), MYC-tagged TrkB (C, D) or MYC-tagged TrkC (E, F). Cell lysates were immunoprecipitated (IP) and
immunoblotted (Blot) with the indicated antibodies. Panels A to F each have three sections, the top and middle sections represent immunoblots of immunoprecipitates
(IP), detected with the indicated antibodies (Blot); the bottom sections each show immunoblots of cell lysates, probed with the indicated antibodies. Within panels
A–F, the exposures times are the same, except for panel B where the middle section is exposed 5× longer, panel D where the middle section is exposed 300×
longer than the upper and lower sections, and panel C where the lower section is exposed 300× shorter than the other sections. Panel G shows schematics of PTPσ
and Trk, indicating the positions of epitope tags, the positions of major protease cleavage in PTPσ (triangles) and the five different protein fragments generated;
these five fragments (1–5) are also indicated on the right of panels A–F. The molecular sizes are indicated to the left of each panel in kDa.
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of TrkA phosphorylation and be prior to significant NGF-
induced TrkA degradation [50]. To prevent the activity of
residual phosphatases in the lysates, sodium orthovanadate was
added to the lysis buffer. Western blot analysis using an anti-
TrkA antibody was first carried out to assess the amounts of
TrkA expression in the transfected cells (Fig. 3A, upper panels).
The Western blots were then re-probed with a general antibody
to phosphotyrosine (4G10) to examine its level in the lysates
(Fig. 3A, lower panels). High levels of tyrosine phosphorylated
bands were seen at the sizes of the TrkA proteins in cells
stimulated with NGF (Fig. 3A, lane 3). Co-expression of PTPσ
with TrkA reproducibly caused a significant decrease in these
tyrosine phosphorylated bands (Fig. 3A, lane 4). Anti-TrkAimmunoprecipitation confirmed that the three major bands seen
in lysates, were indeed tyrosine phosphorylated TrkA (Fig. 3A,
lanes 4 and 5). When the levels of phosphorylated TrkA
proteins was measured by scanning densitometry, we consis-
tently observed a decrease in phosphorylation ranging from
63% to 100% loss of phosphate (n=5). In Fig. 3 we show
examples in which there is 85% (Fig. 3A) or 100% (Fig. 3B)
loss of phosphotyrosine in the presence of PTPσ. Furthermore,
dephosphorylation triggered by PTPσ expression resulted in no
reproducible bias in the relative loss of phosphotyrosine
between the three major TrkA forms. Taken together with the
co-immunoprecipitation studies above, these results show that
PTPσ can directly or indirectly cause the efficient depho-
sphorylation of TrkA.
Fig. 3. Effects of PTPσ and PTPα expression on Trk phosphorylation. HEK
293T cells were transfected with Trk proteins, with or without co-transfected
PTPσ or PTPα. Cells were treated prior to lysis with NGF (TrkA expressors),
BDNF (TrkB expressors), or NT3 (TrkC expressors). (A) Lysates of cells
expressing TrkA and PTPσ were immunoblotted using anti-TrkA (upper panel,
lanes 1–4), then the immunoblots were re-probed with anti-phosphotyrosine
(anti-P/Y) (lower lanes). TrkA was also immunoprecipitated (lanes 5, 6) and
immunoblotted with anti-TrkA, followed by re-probing with anti-phosphotyr-
osine (lower lanes). (B) TrkAwas co-expressed with either PTPσ or PTPα and
immunoprecipitated. Blots were probed first for TrkA (upper lanes), then re-
probed for phosphotyrosine (lower lanes). (C and D) Immunoprecipitates of
cells expressing myc-tagged TrkB or myc-tagged TrkC, co-expressing PTPσ,
were immunodetected with either α-myc (upper panels) or anti-phosphotyrosine
(lower panels). The % values below the lanes indicate the densities of phospho-
Trk bands normalised to the Trk bands above them. The molecular sizes are
indicated in kDa.
Fig. 2. PTPα does not interact stably with TrkA. TrkA was co-expressed with
either HA-tagged PTPσ or HA-tagged PTPα in HEK 293T cells and TrkA
proteins were immunoprecipitated. The immunoprecipitates and lysates were
immunoblotted to detect either TrkA itself (top panel), or HA tag (middle and
lower panels). PTPσ co-precipitates with TrkA (lane 2), whereas PTPα protein
does not (lane 5). The faint band in lanes 4 and 5 is a background signal. The
molecular sizes are indicated to the left of each panel in kDa.
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and from PTPσ-expressing cells (without TrkA) were also
examined following NGF treatment. A low level of tyrosine
phosphorylation was observed in these cell lysates, however the
overexpression of PTPσ alone by the cells did not alter this
basal pattern of tyrosine phosphorylation (Fig. 3A, lanes 1 and
2). PTPσ therefore does not cause a non-specific decrease in
tyrosine phosphorylation of cellular proteins.
Having confirmed that TrkA phosphorylation is reduced by
PTPσ, we also tested the effects of PTPσ on TrkB and TrkC. In
similar co-expression studies in HEK 293T cells, we consis-
tently observed that PTPσ causes efficient dephosphorylation of
both TrkB and TrkC (Fig. 3C, D). Thus, PTPσ can cause direct
or indirect dephosphorylation of all three Trk receptors in this
cell system, even though the co-immunoprecipitation efficien-
cies are distinct (Fig. 1). To test whether the dephosphorylation
of TrkA proteins showed PTP-specificity, we co-expressed the
type V RPTP PTPα and demonstrated that it does not cause a
loss of TrkA-associated phosphotyrosine (Fig. 3B).
3.3. Mapping the domains involved in the interaction between
PTPσ and TrkA
It has previously been shown that the interactions between
transmembrane proteins can be established through a range of
different domains, including extracellular, intracellular and
transmembrane domains [55–58]. To determine the domain
requirements for the interaction between PTPσ and TrkA, two
amino-terminal FLAG-tagged deletion mutants of the PTPσ
protein were generated. PTPσECD lacks most of the intracel-
lular domain of PTPσ, and PTPσICD lacks most of the
extracellular domain (Fig. 4A); both retain the transmembrane
region. Co-immunoprecipitation with TrkA showed that bothPTPσECD and PTPσICD can co-immunoprecipitate with the
full-length kinase receptor (Fig. 4B), suggesting that both these
regions of PTPσ support the interaction.
To determine which domains of the TrkA receptor are
involved in the interaction with PTPσ, a number of deletion
mutants of TrkA were tested [43]. The first series of mutants
maintained the extracellular and transmembrane domains and
progressively deleted the intracellular domain from the C-
terminus. These constructs were named according to the
number of amino acids left in the intracellular domain: for
example, TrkA Trunc80 retained 80 intracellular amino acids.
Regardless of the number of amino acids deleted from the
intracellular domain of TrkA, however, PTPσ was still able to
co-immunoprecipitate with the remaining protein (Fig. 5A). A
further TrkA deletion mutant, where the extracellular domain of
TrkA had been deleted (TrkAICD) [44] was also tested for its
interaction with PTPσ. PTPσ and TrkAICD co-immunopreci-
pitated efficiently (Fig. 5B).
Fig. 4. Co-immunoprecipitation of PTPσ extracellular and intracellular domains
with full-length TrkA. (A) Schematic diagram of full-length PTPσ and TrkA
proteins, alongside their respective deletion mutants used in this study:
PTPσECD and Trktrunc2 contain extracellular and transmembrane domains;
PTPσICD and TrkICD contain transmembrane and intracellular domains.
Circles, immunoglobulin-like domains; squares, fibronectin-like III repeats;
black oblongs, tyrosine phosphatase domains; grey rectangle, kinase domain;
open small circles, FLAG tags. (B) HEK 293T cells were co-transfected with
TrkA and FLAG-tagged PTPσECD or PTPσICD. TrkAwas immunoprecipitated
and blots were probed with anti-TrkA (upper panels) or anti-FLAG (middle
panel). Both PTPσECD and PTPσICD associate with TrkA. Lysates were also
immunoblotted with anti-FLAG to confirm expression of PTPσECD and
PTPσICD (lower panel). The molecular sizes are indicated to the left of each
panel in kDa.
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extracellular nor the intracellular domains of either PTPσ or TrkA
are essential for the interaction between the proteins. This suggests
either that interactions require both intracellular and extracellular
regions, or that interactions might be mediated through the trans-
membrane domain regions. To examine the potential transmem-
brane domain interactions, a combination of the extracellular
deletion and intracellular deletion mutants of both proteins were
co-expressed. First, PTPσECD was co-expressed with TrkAICD,
followed by anti-Trk immunoprecipitation. The two proteins
were found to co-precipitate (Fig. 5C). Second, co-expression of
PTPσICD with TrkATrunc2 showed that these proteins also co-
immunoprecipitated (Fig. 5D). Thus it appears that the
transmembrane and immediate juxtamembrnae regions of the
two proteins may be sufficient to promote their interaction. This
in turn strengthens the possibility, but does not yet prove, that
these two proteins are interacting with each other directly.
3.4. The intracellular domain of PTPσ can dephosphorylate
the TrkA receptor
The intracellular domains of a number of receptor-type
proteins often become constitutively active following theremoval of the extracellular domain [44,59–61]. To determine
if the PTPσ intracellular domain maintains its activity without
the extracellular domain, we examined the level of TrkA tyrosine
phosphorylation when co-expressed with PTPσICD (Fig. 6A).
TrkAwas again stimulated with NGF, immunoprecipitated from
the cell lysates and the level of tyrosine phosphorylation was
examined. Like full length PTPσ (Fig. 3), PTPσICD also greatly
decreased the level of tyrosine phosphorylation of full-length
TrkA (Fig. 6A; in this case b82% of control level). As a negative
control, PTPσECD was also co-expressed with TrkA.
PTPσECD lacks the entire intracellular domain and therefore
does not exhibit any phosphatase activity, however, it is able to
bind to full-length TrkA (Fig. 4). PTPσECD was unable to
decrease TrkA phosphorylation (Fig. 6A).
Removal of the extracellular domain of TrkA causes the
constitutive dimerisation and hyperphosphorylation of the TrkA
receptor [44] (Fig. 6B, lane 2). To determine if either full-length
PTPσ or PTPσ ICD were able to dephosphorylate the cons-
titutively active form of TrkA (TrkAICD), the proteins were co-
expressed and the level of tyrosine phosphorylation of the
immunoprecipitated TrkAICD protein was examined. Interest-
ingly, neither PTPσ, nor PTPσICD was able to alter the
phosphorylation of the activated TrkAICD (Fig. 6B). Thus, loss
of the TrkA ectodomain not only causes chronic activation, but
also makes this enzyme resistant to the de-phosphorylation
capacity of overexpressed PTPσ.
3.5. Overexpression of PTPσ in cultured dorsal root ganglion
(DRG) neurons affects neurite outgrowth but not neuron
survival
The above results indicate that PTPσ can interact with and
dephosphorylate the TrkA receptor. It is therefore possible that
within neurons, PTPσ plays an active part in controlling the
TrkA signalling pathway. To examine this possibility, we asked
whether increased expression of PTPσ in primary dorsal root
ganglion (DRG) neurons could influence two major cell
biological effects of the signalling pathways of TrkA: neurite
outgrowth and cell survival. DRG neurons express PTPσ
endogenously [48] and so should have the physiological
signalling pathways present for this enzyme. We have used
E7 DRG neurons, the majority of which will be dependent on
TrkA activation for differentiation and survival [47,62,63]. We
attempted to determine the actual percentage of TrkA-expres-
sing neurons in our cultures directly, using a TrkA-specific
antibody, but this did not prove technically possible in our
hands.
A FLAG-tagged PTPσ construct was co-transfected with a
GFP vector into the E7 neurons. Cells were cultured for 24 h in
the presence of NGF and then immunostained with an anti-
FLAG antibody to confirm that GFP-positive cells also co-
expressed PTPσ (Fig. 7A). As controls, either empty vector
(pCMV25) or the FLAG-tagged PTPσECD vector was co-
transfected with GFP (Fig. 7A).
Upon plating, DRG neurons lose their neurite processes and
have to regenerate them. The effect of PTPσ expression was
therefore assessed by counting the number of GFP-positive cells
Fig. 5. Co-immunoprecipitation of full-length and truncated PTPσ with TrkA extracellular and intracellular domains. (A) HEK 293T cells were co-transfected with
FLAG-tagged PTPσ and either full-length TrkA or TrkATrunc deletion mutants. Deletions mutants contain the extracellular and transmembrane domains of TrkA and
progressively smaller segments of the intracellular domain. The numbers (80, 30, 10, 6 or 2) refer to the number of intracellular amino acids remaining. TrkA and the
TrkATrunc mutants were immunoprecipitated and immunoblotted with anti-TrkA (upper panel) or with anti-FLAG (middle panel). Lysates were also immunoblotted
to detect PTPσ expression (lower panel). (B) Co-immunoprecipitation of PTPσ and the intracellular domain of TrkA. FLAG-tagged PTPσ was co-expressed in HEK
293T cells with TrkAICD, a deletion mutant retaining the transmembrane and intracellular domains. TrkAICD was immunoprecipitated and immunoblotted with anti-
TrkA (arrow, upper panel; 50 kDa bands are antibody proteins) and anti-FLAG (middle panel). Lysates were immunoblotted to detect PTPσ expression (lower panel).
The numbers to the right of each panel indicate the PTPσ forms described in Fig. 1G. (C) HEK 293T cells were co-transfected with FLAG-tagged PTPσECD and
TrkAICD. TrkAICD was immunoprecipitated (arrow, upper panel) and immunoblots were probed with anti-FLAG for PTPσECD detection. Lysates were also
immunoblotted to detect PTPσECD expression (lower panel). (D) FLAG-tagged PTPσICD and TrkATrunc2 were co-expressed in HEK 293T cells and lysates were
immunoprecipitated with anti-TrkA. Proteins were immunodetected with either anti-TrkA (top panel) or anti-FLAG (middle panel). Lysates were immunoblotted to
detect PTPσICD expression (lower panel). The schematics to the right of each panel correspond to those shown in Fig. 4. The molecular sizes are indicated to the left of
each panel in kDa.
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24 hr (Fig. 7B). This basic parameter of neurite re-growth in
culture was expressed as the number of neurite-producing cells
in test cells, expressed relative to cells transfected with the
vector alone (pCMV25+NGF). In the presence of NGF, PTPσ
overexpression resulted in an approximate 50% decrease in
cells producing neurites compared to the control (Fig. 7B). In
contrast, overexpression of PTPσECD had no significant effect
relative to control (Fig. 7B).
To determine what proportion of the neurons in cultures were
acutely sensitive to NGF for neurite outgrowth, and therefore
TrkA-expressing, we removed NGF from the culture medium
and counted neurite-producing neurons after 24 h. A significant
decrease in the number of neurite producing cells was also
observed without NGF (Fig. 7B), similar in extent to that seen
with PTPσ expression. To assess whether the suppression ofneurite formation by PTPσ was occurring predominantly in
NGF-sensitive neurons, we withdrew NGF from PTPσ-
transfected cultures. This led to a similar decrease in neurite-
containing neurons, with no additive effect (Fig. 7B). These
data suggest that PTPσ is acting principally in the TrkA-
responsive cells and possibly in a common signalling pathway.
TrkA activation following NGF stimulation also promotes
the survival of embryonic DRG neurons. Therefore, in addition
to inhibiting neurite outgrowth by dephosphorylating the TrkA
receptor, PTPσ may also be affecting cell survival. To test this,
cells were immunostained with a neuron-specific antibody (anti
β-tubulin, TuJ1) and the total number of GFP-positive/β-
tubulin-positive cells was counted after 24 h in culture (Fig. 7C).
The overexpression of PTPσ did not have any significant effect
on the total number of β-tubulin positive neurons. However, as
expected, the removal of NGF significantly decreased the
Fig. 6. Effect of PTPσICD expression on full-length TrkA and TrkAICD
phosphorylation. (A) TrkA was co-transfected in HEK 293T cells with FLAG-
tagged constructs of full-length PTPσ, PTP ICD or PTPσECD. Cells were
treated with NGF for 20 min prior to lysis and lysates were immunoprecipitated
with anti-TrkA. The level of precipitated TrkAwas determined by immunoblot
(upper panel). Blots were subsequently re-probed with anti-phosphotyrosine
(anti-P/Y, lower panel). (B) TrkAICD was co-transfected with FLAG-tagged
constructs of full-length PTPσ, PTPσICD or PTPσECD. Lysates were
immunoprecipitated and immunoblotted with anti-TrkA and the level of
TrkAICD determined (arrow, upper panel). Blots were subsequently re-probed
with anti-phosphotyrosine (anti-P/Y, lower panel). In the gel shown, PTPσ and
PTPσICD reduced TrkA phosphorylation (normalised for TrkA level) by 62%
and 82% , respectively. The molecular sizes are indicated to the left of each panel
in kDa.
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absence of NGF, no further decrease in cell survival was seen
with PTPσ overexpression. Together, these results suggest that
PTPσ overexpression can suppress neurite outgrowth following
TrkA activation, but has little effect on the cell survival response
to NGF in this time period.
4. Discussion
The regulation of protein tyrosine phosphorylation is
essential for many cellular processes and actions of tyrosine
kinases must be counterbalanced by the action of tyrosine
phosphatases to ensure the precise control of signal transduction
cascades. In the present study, we show that the neurotrophin
RTKs TrkA and TrkC, but not TrkB, are readily found in
complexes with the RPTP PTPσ. Mapping experiments of the
TrkA and PTPσ interaction indicate that the transmembranedomain regions may be sufficient to promote a significant
degree of this interaction either directly or indirectly. Further-
more, we show that even though PTPσ appears to form different
kinds of complexes with the neurotrophin receptors, it is still
able to dephosphorylate all of them, at least under conditions in
HEK 293T cells. We also show in primary DRG neurons that
the overexpression of PTPσ suppresses the NGF-induced re-
growth of neurites, but does not affect cell survival, suggesting
that PTPσ differentially regulates TrkA-dependent signalling
pathways in sensory neurons.
Studies carried out previously have indicated a regulatory
relationship between several RPTPs and RTKs. PTPσ over-
expression in the A431 cell line reduces phosphorylation of the
EGF receptor [34]. In C. elegans, FGF receptor signalling is
negatively regulated by the RPTP Clr1 [64], while in human
U2OS cells, LAR inhibited FGF-induced MAP kinase activa-
tion [35]. More recently, the Met tyrosine kinase was shown to
be a substrate of DEP-1 [65], while Eph receptors are negatively
regulated by PTPro [66]. Recently, direct associations sugges-
tive of complex formation between RPTPs and RTKs have also
been demonstrated for the type IIa RPTP LAR and TrkA [38].
This interaction is also associated with suppression of TrkA
signalling [38]. Furthermore, reduction in LAR expression in
PC12 cells causes reduced cell death, increased neurite
outgrowth and increased responsiveness to NGF, all of which
support the possibility that LAR directly dephosphorylates
TrkA. Our studies have now concluded that the related type IIa
RPTP, PTPσ, also associates stably with and dephosphorylates
TrkA, suppressing neurite outgrowth. Unlike LAR, however,
PTPσ did not affect cell survival. It is also noteworthy that
cytoplasmic PTPs, including SHP-1, have been shown to
downregulate Trk signalling [67]. Depending on the neural cell
type, there may therefore be a complicated interplay between
several RPTPs and cytoplasmic PTPs, for Trk homeostasis.
In examining the interaction between PTPσ and the other Trk
family members, PTPσ was found to associate strongly with
TrkC, but very weakly with TrkB. Interestingly, recent work
with LAR shows that it can associate indirectly with TrkB and
activate it [39], while interactions of LAR with TrkA (either
direct or indirect) are distinct and cause TrkA inactivation [38].
Our data show that although PTPσ binds very poorly to TrkB, it
can still cause its dephosphorylation, at least in HEK 293T cells.
Thus LAR and PTPσ appear to form distinct complexes with
Trk, compared to TrkA and TrkC, but while LAR and PTPσ
have similar influences over TrkA, they have opposing in-
fluences over TrkB activation . The indirect interaction of LAR
with TrkB appears to be via pp60src [38]. It will be of interest
therefore to see if the interactions of PTPσ with TrkA, TrkB or
TrkC also occur via such tyrosine kinases. Another prediction
from our data is that experimental downregulation of PTPσ
levels in DRG neurons may stimulate NGF activity and neurite
outgrowth. Although this remains to be tested using RNAi for
example, we know already that PTPσ-deficient neurons do
exhibit increased neurite extension rates [26–28].
The requirement for PTPσ to interact differentially with the
three Trk receptors, may reflect its need to differentially regulate
signalling pathways in cells expressing multiple Trk types. At
Fig. 7. Effect of PTPσ overexpression on DRG neurite outgrowth and survival. (A) E7 chick DRG neurons were co-transfected with a GFP expression vector and
vectors containing either no insert (pCMV25), or FLAG-tagged PTPσ, or FLAG-tagged PTPσECD. Cells were cultured for 24 h on a fibronectin substrate and were
then fixed and immunostained with anti-FLAG. Examples of GFP-expressing, transfected cells are shown. (B) Transfected neurons were cultured in the presence or
absence of NGF and the number of GFP-positive neurons with neurites greater than 1 cell body in length were counted (see Materials and methods). The number of
neurite-producing cells within a standard area is expressed as a percentage relative to the pCMV25+NGF control. Error bars=2× SEM; double asterisks show b0.001
significance in t-tests in comparison with the control. (C) Transfected cells were immunostained with anti-neuronal β-tubulin and the number of GFP-positive/
β-tubulin-positive cells was counted. Cell numbers are expressed as a percentage relative to the pCMV25+NGF control. Error bars=2× SEM; asterisk indicates
b0.01 significance relative to the pCMV25+NGF control.
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different Trk receptors is highly overlapping. During early DRG
development for example, the majority of immature neurons
express TrkC, with greater than 60% of these cells also
expressing TrkA and/or TrkB [47]. The regulation of the Trk
receptor activity by PTPσ may therefore be required to
differentiate between simultaneous activation of the Trk recep-
tors, allowing preferential activation and downstream signalling
of a single receptor. Further regulation of Trk signalling by PTPσ
may also occur through the regulated expression of the PTPσ
ligands, which include heparin sulphate proteoglycans agrin and
collagen XVIII [68], and nucleolin [69]. It has been suggested
that ligand binding inhibits PTPσ activity [16,40,70], which in
our model would promote TrkA signalling. Further, overlapping
control over Trk signalling would be provided by the expression
of LAR in neurons, and possibly PTPδ. LAR and PTPσ are co-
expressed in DRG neurons [71], but in motor neurons, where
only TrkB and TrkC are expressed in mammals, only PTPσ and
PTPδ, not LAR, are expressed [72–74]. A full understanding of
how each of these type IIa RPTPs interacts with the three
neurotrophins receptors may therefore allow us to understand
further how these phosphatases act cooperatively or antagonis-
tically in different neuronal types. This may relate to what has
been found in Drosophila axons, where RPTPs both cooperate
and compete to control axon targeting [11].One caveat with overexpression systems is that non-specific
interactions may be observed between proteins. However, the
fact that PTPσ selectively interacted with TrkA/C and not
TrkB, indicates a degree of specificity. Furthermore, the
specificity of the interaction from the standpoint of PTPσ is
supported by the fact that we see no evidence of interactions
between PTPα and TrkA in this cell system. We have not,
however, been able to examine the interaction between PTPσ
and TrkA at a more physiological level in primary neurons as
yet, due to their low levels of expression and the lack of
sensitivity of current antibodies.
Our molecular analysis demonstrated that the transmem-
brane and juxtamembrane domains of TrkA and PTPσ were
sufficient to allow interaction at the level of co-precipitation.
Although it remains to be proved whether this is a direct
interaction, it does seems likely since co-precipitation occurred
between both the TrkA ectodomain/PTPσ intracellular domain,
as well as the PTPσ ectodomain/TrkA intracellular domain. The
involvement of the transmembrane domain in the homo- and
hetero-dimerisation of other RPTPs and RTKs has been
described [55–58]. Furthermore, transmembrane domains are
required for the interaction of other membrane-associated
proteins with RPTPs and RTKs [75,76], including the
association between TrkA and one of its substrates, ARMS
[75,77]. The association between the transmembrane domains
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interaction between PTPσ and TrkA/TrkC, but not TrkB, since
the homology of the transmembrane domains of Trks show that
TrkA and TrkC are the most closely related (42% amino acid
conservation). It will therefore be of interest to test directly
whether the transmembrane domains do indeed, directly
engender interaction specificity.
The removal of the extracellular domain of PTPσ did not
affect its ability to either associate with, or dephosphorylate
TrkA. This indicates that the extracellular domain of PTPσ is not
required in order to target this kinase. It is possible instead that
the extracellular domain of the RPTP is necessary in vivo to
receive direct negative regulation by ligands. The depho-
sphorylation of TrkA by PTPσ could, nevertheless, be overcome
when a constitutively activated form of TrkA was used.
Although still associating with PTPσ, the kinase was maintained
in a highly phosphorylated state. It is not clear, however, whether
this TrkA mutant has a novel and abnormal, dimerised
conformation, preventing RPTP access to tyrosine substrate
sites. The data nonetheless demonstrate that chronic activation
of RTKs, as often seen in their oncogenic forms, may not only be
ligand-independent, but also resistant to the action of RPTPs.
Signalling via the TrkA receptor regulates cell differentiation,
neurite outgrowth and cell survival [54]. As expected therefore,
we found that the removal of NGF from DRG neurons in vitro
reduced both cell survival and neurite outgrowth. The over-
expression of PTPσ in DRG neurons treated with NGF also
decreased neurite outgrowth. This is in keeping with studies
examining the inhibition of PTPσ activity, where neurite
outgrowth was increased [16,40], and with the enhanced nerve
regeneration seen in PTPσ deficient animals [26–28]. The
neurite-suppressing effect of PTPσ on DRG neurons, however,
was not enhanced by NGF withdrawal, suggesting that PTPσ is
acting within the TrkA population and via the TrkA pathway.
Significantly, PTPσ overexpression did not affect cell survival in
this context. This is in contrast to LAR, where the antisense
downregulation or peptide inhibition of LAR activity affected
both neurite growth and cell survival in the PC12 neuronal cell
line [36,38]. TrkA receptor activation leads to the phosphoryla-
tion of ten evolutionary conserved tyrosine residues, three of
which are in the activation loop of the kinase domain, while
phosphorylation of the other residues creates docking sites for
various proteins, leading to the activation of distinct downstream
pathways [54]. In the DRG neurons therefore, PTPσmay act on
TrkA to dephosphorylate selectively only those residues that
influence the neurite-outgrowth pathway. The 4G10 anti-
phosphotyrosine does not distinguish between the TrkA
phosphorylation sites in the present study and PTPσ was seen
to completely dephosphorylate TrkA in some 293Texperiments.
In order therefore to determine if PTPσ can selectivity target
TrkA tyrosines under physiological conditions, we will need to
assess endogenous dephosphorylation with TrkA-specific,
phospho-dependent antibodies.
In DRG neurons our data are consistent with the possibility
that PTPσ is directly targeting tyrosines on TrkA, however it
remains possible that PTPσ is instead (or in addition) targeting a
downstream component of the TrkA signalling pathways. Thenucleofection method used in this study does not presently
provide a sufficient transfection efficiency to allow a biochem-
ical analysis of this question in primary neurons.
In summary, we have shown that PTPσ interacts stably with
two of the three high affinity neurotrophin receptors, while being
able to induce dephosphorylation of all three in 293T cells. The
insensitivity of TrkA to PTPα further suggests that only certain
RPTPmembers operate in Trk biochemical pathways. PTPσ can
also downregulate the NGF-dependent, neurite-promoting
signal pathway in primary sensory neurons, while not affecting
cell survival. Given the related studies documented for LAR, the
intriguing possibility arises that different type IIa RPTPs may
not only differentially up- and downregulate Trk enzymes, but
also may target distinct signalling pathways downstream of each
Trk class.
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